Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794754 | 0.88 | L3MBTL1 (0.66) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL30167630 | 0.88 | L3MBTL1 (0.66) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL2482690 | 0.87 | L3MBTL1 (0.71) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL10775846 | 0.86 | L3MBTL1 (0.67) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL10775946 | 0.86 | L3MBTL1 (0.67) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL43317 | 0.86 | L3MBTL1 (0.67) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL11874439 | 0.83 | L3MBTL1 (0.64) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL2094937 | 0.82 | MEN1 (0.58) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL11662071 | 0.81 | L3MBTL1 (0.62) | L3MBTL1MAPTTDP1TSHRCYP1A2 | |
| SCHEMBL9440806 | 0.81 | CYP1A2 (0.60) | L3MBTL1MAPTTDP1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310496-B1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA CORP (JP) | 2006-12-06 | — | — | EP | claimed |
| US-6916939-B2 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA KAGAKU KOGYO K.K. (JP) | 2005-07-12 | — | — | US | claimed |
| US-20030191326-A1 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA CORPORATION (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1310496-A1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-05-14 | — | — | EP | claimed |
| CN-116897151-A | Process for producing glycolide | 株式会社吴羽 | 2023-10-17 | — | — | CN | disclosed |
| CN-111741952-B | Process for producing glycolide | 株式会社吴羽 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022196178-A1 | METHOD FOR PRODUCING GLYCOLIDE | 株式会社クレハ | 2022-09-22 | — | — | WO | disclosed |
| CN-110072856-B | Process for producing alpha-hydroxycarboxylic acid dimer cyclic ester | 株式会社吴羽 | 2022-03-15 | — | — | CN | disclosed |
| CN-111741953-B | Method for producing glycolide | 株式会社吴羽 | 2021-05-28 | — | — | CN | disclosed |
| CN-111757873-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-09 | — | — | CN | disclosed |
| CN-111741953-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-02 | — | — | CN | disclosed |
| CN-111741952-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-02 | — | — | CN | disclosed |
| US-20110263875-A1 | Production Process of Glycolide | KUREHA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2377858-A1 | METHOD FOR PRODUCING GLYCOLIDE | Kureha Corporation (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168446-A1 | METHOD FOR PURIFICATION OF CYCLIC ESTER | KUREHA CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2128151-A1 | METHOD FOR PURIFICATION OF CYCLIC ESTER | Kureha Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1310496-B1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA CORP (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6916939-B2 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA KAGAKU KOGYO K.K. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030191326-A1 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1310496-A1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191326-A1 | Process for the preparation of cyclic esters and method for purification of the same | CEL, CETP, MCCC2 | L3MBTL1 4166/4885MAPT 1560/4885TDP1 1365/4885 |
| US-20110263875-A1 | Production Process of Glycolide | RPN2, RPN1, DDOST | L3MBTL1 4701/4885MAPT 910/4885TDP1 3007/4885 |
| US-20100168446-A1 | METHOD FOR PURIFICATION OF CYCLIC ESTER | MCCC2, CCDC47, HACD3 | L3MBTL1 4388/4885MAPT 1567/4885TDP1 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.